Core Insights - Silo Pharma has entered into a service agreement with Resyca BV for a drug-device study of its lead asset SPC-15, aimed at treating PTSD through a microchip-based nasal spray system [1][2] - The study is expected to provide final device data and documentation necessary for the FDA IND submission planned for this year [2] - SPC-15 is a serotonin 5-HT4 receptor agonist targeting stress-induced psychiatric disorders, with potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway [3] Company Overview - Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases [5] - The company's portfolio includes innovative programs such as SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain, along with preclinical assets targeting Alzheimer's disease and multiple sclerosis [5] Partner Overview - Resyca BV, founded in 2020, specializes in developing and manufacturing soft mist inhalation and nasal spray devices, utilizing proprietary micro-nozzle technology [4] - Resyca is a joint venture between Bespak Limited and Medspray Pharma BV, offering comprehensive services from early-stage development to commercial production [4]